Published in Front Radiat Ther Oncol on January 01, 1988
Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol (2007) 1.24
Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. Neuro Oncol (2010) 0.82
Hyperfractionated radiotherapy for T2 glottic cancer for preservation of the larynx. Eur Arch Otorhinolaryngol (2005) 0.82
Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell (2015) 0.81
Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre. Strahlenther Onkol (2013) 0.78
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys (2000) 7.50
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med (1992) 5.14
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck (2005) 4.27
Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst (2000) 4.15
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer (1979) 2.67
Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57
Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys (1995) 2.50
New manzamine alkaloids with potent activity against infectious diseases. J Am Chem Soc (2001) 2.35
A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys (1996) 2.29
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol (1997) 2.23
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol (1997) 2.17
High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer (1995) 2.10
Is there a future for neutron capture therapy? Int J Radiat Oncol Biol Phys (1996) 2.08
Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. Int J Radiat Oncol Biol Phys (1990) 2.07
Bone mineral affection in asymptomatic adult patients with celiac disease. Am J Gastroenterol (1994) 2.04
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer (2001) 1.91
Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr (1992) 1.89
Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys (1993) 1.85
Risk factors in breast-conservation therapy. J Clin Oncol (1994) 1.82
Evolutionary relationships within the fungi: analyses of nuclear small subunit rRNA sequences. Mol Phylogenet Evol (1992) 1.80
Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol (2000) 1.76
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys (1997) 1.70
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci (1982) 1.67
Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol (1988) 1.61
The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys (1995) 1.60
EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia (2012) 1.60
EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys (1995) 1.59
Effects of continuous hyperfractionated accelerated and conventionally fractionated radiotherapy on the parotid and submandibular salivary glands of rhesus monkeys. Radiother Oncol (1995) 1.58
EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol (1995) 1.58
The impact of treatment time and smoking on local control and complications in T1 glottic cancer. Int J Radiat Oncol Biol Phys (1998) 1.57
Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol (1998) 1.55
Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. Int J Radiat Oncol Biol Phys (1996) 1.53
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol (2000) 1.53
Higher plant mitochondria encode an homologue of the nuclear-encoded 30-kDa subunit of bovine mitochondrial complex I. Eur J Biochem (1993) 1.50
Organization of ribosomal DNA in the basidiomycete Thanatephorus praticola. Curr Genet (1990) 1.50
Measurement of the depth of maximum of extensive air showers above 10{18} eV. Phys Rev Lett (2010) 1.48
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res (1999) 1.48
Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol (2001) 1.43
Peripheral nerve regeneration: the effects of postoperative irradiation. Plast Reconstr Surg (1997) 1.42
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer (2005) 1.40
Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys (1996) 1.40
Separate branches of the uvr gene-dependent excision repair process in ultraviolet-irradiated Escherichia coli K-12 cells; their dependence upon growth medium and the polA, recA, recB, and exrA genes. J Bacteriol (1974) 1.39
[Radiotherapy of the neck as a risk factor for stroke]. Ned Tijdschr Geneeskd (2005) 1.38
Plea for a preoperative adjuvant approach in the management of rectal cancer. Int J Radiat Oncol Biol Phys (1994) 1.38
[Internal radiotherapy in prostatic carcinoma; disappointing long-term results of retropubic Iodine-125 implantation]. Ned Tijdschr Geneeskd (1996) 1.38
[A solitary sternal lesion found by skeletal scintigraphy following treatment for breast carcinoma]. Ned Tijdschr Geneeskd (2007) 1.38
Radiation nephropathy in the rhesus monkey: morphometric analysis of glomerular and tubular alterations. Int J Radiat Oncol Biol Phys (1995) 1.37
The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int J Radiat Oncol Biol Phys (1990) 1.37
Radiation-induced apoptosis. Cell Tissue Res (2000) 1.36
Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer (1994) 1.35
Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. Eur Urol (1982) 1.35
Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys (1997) 1.33
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer (2000) 1.31
Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer (1995) 1.31
Psychological effects of breast conserving therapy in comparison with radical mastectomy. Int J Radiat Oncol Biol Phys (1985) 1.31
Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). Eur J Cancer Clin Oncol (1989) 1.30
Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol (1997) 1.29
Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer (2008) 1.29
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol (2011) 1.28
Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer (2013) 1.27
The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer. Int J Radiat Oncol Biol Phys (1997) 1.26
Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol (1988) 1.23
Risk of fractures in celiac disease patients: a cross-sectional, case-control study. Am J Gastroenterol (2000) 1.23
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer (2003) 1.22
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol (1994) 1.21
Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia (2010) 1.19
Prognostic variables in parotid gland cancer. Arch Otolaryngol Head Neck Surg (1991) 1.19
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys (1999) 1.18
Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res (1999) 1.18
High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol (2003) 1.17
Tissue tolerance to reirradiation. Semin Radiat Oncol (2000) 1.17
Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol (1997) 1.17
Acute and late radiation injury in rhesus monkey parotid glands. Evidence of interphase cell death. Am J Pathol (1986) 1.16
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2002) 1.16
The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol (1987) 1.14
Characterization of a new sporulation factor in Bacillus subtilis. J Bacteriol (1993) 1.14
Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases. Br Med J (Clin Res Ed) (1984) 1.14
Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys (2000) 1.13
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia (2012) 1.12
Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations. Radiother Oncol (1988) 1.12
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol (1998) 1.11
The World Trade Center attack. Doctors in the fire and police services. Crit Care (2001) 1.11
Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res (1999) 1.11